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Clinical Trials
Proton Pump Inhibitors May Reduce the Efficacy of Clopidogrel
Clopidogrel is a prodrug thatmust undergo several transformations before becom-ing metabolically active; one of the transformations utilizes the isoenzyme
CYP2C19, which is also involved in themetabolism of several proton pump inhibitors
(PPIs). Gilard and colleagues randomized post-percutaneous coronary intervention
(PCI) patients receiving clopidogrel and aspirin to either omeprazole or placebo and
assessed the efficacy of clopidogrel by measuring vasodilator-stimulated phosphopro-
tein phosphorylation. Omeprazole significantly decreased the antiplatelet effect of
clopidogrel; subjects receiving omeprazole were twice as likely to be classified as
non-responders. This study suggests a significant drug–drug interaction between ome-
prazole, and potentially other PPIs, and clopidogrel. The authors caution against the
routine use of PPIs in post-PCI patients. See page 256. See figure.
Coronary Heart Disease
Impaired Fasting Glucose Increases Cardiovascular Risk in Women
In 1997, the American Diabetes Association introduced the concept of impairedfasting glucose (IFG) for those with a fasting plasma glucose (FPG) level of 110 to
125 mg/dl. An FPG over 125 mg/dl defines diabetes. In 2003, the threshold for IFG
was lowered to 100 mg/dl, but there is little known about the cardiovascular risk
associated with either definition. Levitzky and colleagues used data collected from the
FraminghamOffspring Study to compare the two definitions for predicting medium-
term (4 year) cardiovascular risk. Neither IFG definition identifiedmen at increased
risk. In women, there was increased risk, especially in those with FPG110mg/dl.
Women with an FPG of 110 to 125 mg/dl had similar cardiovascular risk as did
women with diabetes. These results suggest that FPG 110 mg/dl identifies
women at increased cardiovascular risk, whereas the threshold may be higher in
men. See page 264.
Page 273
Coronary Heart Disease
Ethanol Negates the Benefits of Ischemic Preconditioning
Ischemic preconditioning is a phenomenon whereby repeated episodes of ischemiaproduce less negative effects. Niccoli and colleagues noted that in animal models,
ethanol seems to abolish this effect, and so they studied it in humans. Thirty patients
undergoing percutaneous coronary intervention underwent 2 episodes of occlusive
intracoronary balloon inflations separated by 5 min; one-half of the subjects ingested
149ml of Gordon’s Gin, approximately 5 oz, 30min before the study. The control
patients had less intracoronary ST-segment elevation during the second balloon
inflation, whereas there was increased ischemia in those assigned to ethanol. This
study confirms that ethanol negates the benefits of ischemic preconditioning.
See page 271. See figure.
(continued) A-38Heart Rhythm Disorders
Risk Stratification for Syncope
Syncope accounts for 3% of all emergency department visits and 6% of hospitaladmissions, yet its prognosis and management varies widely. The STePS (Short-
Term Prognosis of Syncope) study followed nearly 700 subjects who presented with
syncope. Six percent of subjects experienced severe outcomes in the 10 days after
presentation. Risk factors for short-term severe outcomes were an abnormal electrocar-
diogram, concomitant trauma, absence of symptoms of impending syncope, andmale
gender. Outcomes after the initial 10 days, but less then 1 year later, occurred in an
additional 9% of patients. Risk factors for these events were age65 years, history of
neoplasms, cerebrovascular diseases, structural heart diseases, and ventricular arrhyth-
mias. This study helps to identify patients with syncope who need more aggressive
monitoring. See page 276.
Page 301
Heart Failure
Elevated Abdominal Pressure Contributes
to Renal Dysfunction During Heart Failure Decompensation
Patients with decompensated heart failure may have elevated intra-abdominalpressure (IAP), but little is known about the hemodynamic effects of IAP or its
effects on renal function.Mullens and colleaguesmeasured IAPusing amodified Foley
catheter in patients with ejection fraction30% admitted with decompensated heart
failure. All subjects also had pulmonary artery catheters placed and were treated with
diuresis and/or vasodilator therapy. Elevated IAP (8mmHg) was directly associated
with worse renal function; medical therapy improved both hemodynamic mea-
surements and IAP. However, the reduction in IAP was a better predictor of
improved renal function than any hemodynamic measurement. These results
suggest that elevated IAP may be a significant component of the cardio-renal
syndrome. See page 300. See figure.
